SAN DIEGO--(BUSINESS WIRE)--AltheaDx, Inc. is pleased to announce the recent publication of two studies that demonstrate the value of IDgenetix® pharmacogenetic testing. The first study, published January 19, 2016 in the online journal Pharmacogenomics and Personalized Medicine1, demonstrated that savings in health care costs for patients in a long-term care setting taking five or more medications (polypharmacy) can be achieved by incorporating pharmacogenetic information into their medication management. Specifically, the authors found that half of the study group had an actionable finding, and an overall cost benefit was recognized by utilizing IDgenetix® testing.
